Hema Now: Episode 20: The Science Behind Myelodysplastic Syndromes Kevin Rouault-Pierre and Onima Chowdhury explore the molecular roots of myelodysplastic syndromes, and their implications for future care.

Thanks for the Podcast Helena Bradbury and Jonathan Sackier. We really enjoyed the discussion! #MDS #SF3B1 #VitaminB5 & #AcademicLife📻 🩸

www.emjreviews.com/hematology/p...

One of our latest! We hope you enjoy! Led by @ShoshanaBurke & in collaboration with @OnimaChowdhury 🎉🎊. #MDS #SF3B1 #VitaminB5 #Leukemia

Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients A deep understanding of the biological mechanisms driving the pathogenesis of myelodysplastic neoplasms (MDS) is essential to develop comprehensive therapeutic approaches that will benefit patient's ...

4/4
📖 And fresh off the press in @hemasphere-journal.bsky.social : our new review with @ShoshanaBurke & @OnimaChowdhury— "Low-risk MDS: A spotlight on precision medicine for SF3B1-mutated patients", covering the biological & clinical landscape of SF3B1-MDS.
📢 #MDS #SF3B1

onlinelibrary.wiley...

SF3B1 thermostability as an assay for splicing inhibitor interactions - PubMed The spliceosome protein, SF3B1 associates with U2 snRNP during early spliceosome assembly for pre-mRNA splicing. Frequent somatic mutations in SF3B1 observed in cancer necessitates characterization of...

New work from Melissa J's lab on #SF3B1!

pubmed.ncbi.nlm.nih.gov/39725033/

Cover of the WHO classification.

In 2008, the World Health Organization (WHO) changed FAB's term "ringed" sideroblast to "ring", since "ring" was the term originally used by Björkman.

And in 2016, WHO decided MDS with ring sideroblasts could include cases with as few as 5% ring sideroblasts if a mutation in #SF3B1 was present./7